<DOC>
	<DOCNO>NCT02368587</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy intracoronary intravenous infusion human umbilical Wharton 's jelly-derived Mesenchymal Stem Cell ( WJMSC ) patient ischemic cardiomyopathy secondary myocardial infarction .</brief_summary>
	<brief_title>Intracoronary Intravenous Infusion Human Wharton ' Jelly-derived Mesenchymal Stem Cells Patients With Ischemic Cardiomyopathy</brief_title>
	<detailed_description>Ischemic heart failure ( IHF ) secondary myocardial infarction common , lethal , disabling , expensive condition . Despite advance last 30 year , prognosis patient IHF remain poor . At present , increase interest attempt repair fail heart use stem cell , since approach potential regenerate dead myocardium thus alleviate underlying cause IHF . A primitive population mesenchymal stem cell ( MSCs ) isolate continuum sub-amnion perivascular region umbilical cord , refer Wharton 's jelly-derived MSCs ( WJMSCs ) . WJMSCs retain combination embryonic stem cell ( ESC ) MSC marker primary culture early passage , thus retain multipotent stem cell characteristic . Preclinical study demonstrate WJMSCs induce differentiate cardiomyocytes endothelial cell integrate vasculature ischemic cardiac tissue , well improve heart function significantly . Therefore , investigator perform double-blind , placebo-controlled trial , randomly assign 160 patient ischemic heart failure secondary myocardial infarction receive intracoronary intravenous infusion WJMSCs placebo , investigate therapeutic safety efficacy WJMSCs patient ischemic cardiomyopathy .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<criteria>1 . Age limit 2 . Patient must provide write informed consent . 3 . Have diagnosis chronic ischemic leave ventricular dysfunction secondary myocardial infarction ( MI ) define follow 3 criterion : Previous MI document clinical history include elevation cardiac enzymes and/or electrocardiogram ( ECG ) change consistent MI . Patients treat thrombolytic therapy percutaneous coronary revascularization . Screening CMRI show area akinesis , dyskinesis , severe hypokinesis associate evidence myocardial scar base delayed hyperenhancement gadolinium infusion . 4 . Patient treat appropriate maximal medic al therapy ICMP . For β blockade , patient must en stable dose clinically appropriate βblocker 3 month . For angiotensinconverting enzyme inhibition , patient must stable dose clinically appropriate agent 1 5. leave ventricular ejection fraction ( LVEF ) &lt; 45 % echocardiogram , CMRI , leave ventriculogram within prior 6 6 . Patients candidate cardiac catheterization assignment intracoronary infusion group ; patient nocandidate cardiac catheterization assignment intravenous infusion group . 1 . Have baseline glomerular filtration rate &gt; 50 mL/min per 1.73 m2 2 . Evidence lifethreatening arrhythmia ( ventricular tachycardia complete heart block ) screen ECG.. 3 . Have hematologic abnormality evidence hematocrit &lt; 25 % , white blood cell &lt; 2500/u L platelet value &lt; 100000/u L without another explanation . 4 . Have liver dysfunction , evidence enzyme ( aspartate aminotransferase alanine aminotransferase ) &gt; 3× upper limit normal . 5 . Have coagulopathy ( international normalize ratio &gt; 1.3 ) reversible cause ( ie , coumadin ) . 6 . Have contraindication performance CMRI ( CMRIs perform patient pacemaker pacemaker dependent ) . 7 . Be organ transplant recipient . 8 . Have clinical history malignancy within 5 except curatively treat basal cell carcinoma , squamous cell carcinoma , cervical carcinoma . 9 . Have noncardiac condition limit lifespan &lt; 1y . 10 . Have history drug alcohol abuse within past 24 m. 11 . Be serum positive human immunodeficiency virus , hepatitis B surface antigen , hepatitis C. 12 . Be female pregnant , nursing , childbearing potential practicing effective contraceptive method .</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>intracoronary infusion</keyword>
	<keyword>intravenous infusion</keyword>
	<keyword>Wharton 's jelly-derived mesenchymal stem cell</keyword>
	<keyword>ischemic Cardiomyopathy</keyword>
	<keyword>heart function</keyword>
</DOC>